Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Shares Outstanding (Weighted Average) (2019 - 2025)

Maxcyte (MXCT) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $106.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.43% to $106.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $106.6 million, a 1.43% increase, with the full-year FY2024 number at $104.8 million, up 1.53% from a year prior.
  • Shares Outstanding (Weighted Average) was $106.6 million for Q3 2025 at Maxcyte, roughly flat from $106.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $106.6 million in Q3 2025 to a low of $81.0 million in Q1 2021.
  • A 5-year average of $100.4 million and a median of $103.0 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 43.18% in 2021, then rose 1.21% in 2024.
  • Maxcyte's Shares Outstanding (Weighted Average) stood at $90.6 million in 2021, then rose by 12.23% to $101.7 million in 2022, then rose by 1.54% to $103.3 million in 2023, then increased by 1.53% to $104.8 million in 2024, then grew by 1.68% to $106.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Shares Outstanding (Weighted Average) are $106.6 million (Q3 2025), $106.4 million (Q2 2025), and $106.0 million (Q1 2025).